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McCormick, an American epidemiologist formerly with the Centers for Disease Control and Prevention (CDC) in Atlanta, won't have to knock on brewery doors in his new job. As head of a recently created epidemiology and biostatistics unit at the Pasteur Institute in Paris, the veteran virus hunter will be able to carry on his research in relative scientific luxury. And he is joined in France by his British wife and virus-hunting colleague, former CDC physician Susan Fisher-Hoch, who is overseeing the construction of Europe's first full-scale, top-security microbiology lab in Lyons (see sidebar).
It may seem strange that this duo, whose adventures in Africa and Asia have been featured in several recent books and television documentaries, has traded the hardships of the developing world for the advanced scientific environment of France and the bistros of Paris and Lyons. "I was a little bit surprised that they went to France," says Mann, who is now dean of the Allegheny University School of Public Health in Philadelphia. "They are entering a citadel of modern medicine with a message about public health" in the developing world. But McCormick and Fisher-Hoch intend to continue focusing on problems of the Third World countries in which they spent much of their careers. One of McCormick's key tasks will be to create an epidemiology training program for the worldwide network of Pasteur institutes, most of which are in Asia, Africa, and South America. And among the first projects Fisher-Hoch hopes to carry out at the new lab she http://webl2.epnet.com/delivery.asp?tb=l&_ug=dbs+7+ln+en-us+s ... is setting up in Lyons is the development of a vaccine against Lassa fever, which infects at least 100,000 people in Africa each year and causes up to 5000 deaths. The couple's journey from Atlanta to France followed a circuitous route. In 1993, they left the CDC and moved to Karachi, Pakistan, when the Aga Khan University offered McCormick a position as head of its community health sciences department. They left the CDC in part because they felt that over the years the agency had become "political and bureaucratic," McCormick says. "The big watershed," Fisher-Hoch adds, was a falling-out with some colleagues at CDC over how best to handle a 1989-90 outbreak of Ebola at a private monkey facility in Reston, Virginia, that received widespread media coverage. McCormick--who was head of CDC's special pathogens branch at the time--believes the dangers to the public were greatly exaggerated. In Karachi, the two were in their element, training medical students to track down hepatitis C and cholera and trying to boost the underdeveloped public health system in Pakistan.
Then, in late 1996, as their contract at Aga Khan University was coming to an end, McCormick learned from a former colleague at CDC that the Pasteur Institute was looking for someone to create a new epidemiology unit. McCormick sent an e-mail message to Pasteur medical director Philippe Sansonetti expressing interest. The e-mail never went through, but Pasteur officials, it turns out, were already interested in McCormick. At almost exactly the same time, Pasteur director-general Maxime Schwartz visited New York and dropped by to see Newsday reporter Laurie Garrett, whose book, The Coming Plague, features McCormick prominently. Schwartz, who had read the book, asked Garrett how to contact McCormick and eventually telephoned him in Karachi.
In an interview with Science, Sansonetti said that the creation of an epidemiology unit at Pasteur is part of a drive to focus the institute's basic research talents more directly on public health problems, particularly infectious diseases. "We already have some instruments for doing this, such as our international network of Pasteur institutes, but we did not have sufficient visibility in the hospitals and in the field. An epidemiology unit will give us this visibility and allow the institute to insert itself into the area of new pathogens and [drug-) resistant organisms." Asked why McCormick, an American, was chosen to head the new unit, Sansonetti says that while France has some excellent epidemiologists, their training tends to be oriented toward fundamental research rather than pragmatic field experience. "Joe McCormick, who has experience in molecular biology as well as in the field, responded better to the profile" the institute was looking for, Sansonetti says.
McCormick says he came to Pasteur to "develop epidemiology as a scientific tool" that would bridge the gap between basic research and specific public health problems. He says he hopes to use the Pasteur network to create vaccine testing centers in the developing world, particularly focusing on exotic diseases that receive little attention from the pharmaceutical industry. One of his first projects will be to find new "high-powered molecular biology techniques" for developing molecular probes to identify new pathogens in patients. McCormick hopes that this program, which will begin as a collaboration with hospitals and clinics in France, will eventually be put to use in overseas Pasteur institutes.
And if McCormick does find any dangerous new microbes, he will be able to study them in Fisher-Hoch's new lab in Lyons, just 2 hours away by high-speed train. 
EUROPE'S FIRST HIGH-SECURITY PATHOGENS LAB
LYONS --The timing was perfect. In late 1996, Charles Merieux, patriarch of the Lyons-based family of vaccine producers, was looking for someone to build and run a high-containment lab to conduct research on some of the world's most deadly pathogens. Susan Fisher-Hoch--a virologist who had spent much of her career working in such a facility at the Centers for Disease Control and Prevention (CDC) in Atlanta--had just the background for the job. And she happened to be interested in working in France: She and her husband, virologist Joe McCormick, were coming to the end of a joint appointment in Karachi, Pakistan, and http://webl2.epnet.com/delivery.asp?tb=l&_ug=dbs+7+ln+en-us+s ... The new $8 million lab will open later this year at the site of the former Pasteur Institute in Lyons, which closed in 1997. It will be Europe's first full-size, maximum-containment--or biosafety level4 (BSL4)--facility and one of just a handful of such labs in the world. Fisher-Hoch says one of the first projects she hopes to carry out in the lab is the development of a vaccine against Lassa fever, work she began at CDC. Other projects will include research to develop molecular diagnostic tools to quickly detect the viruses that cause hemorrhagic fevers, as well as animal studies into how these microbes cause circulatory system collapse and other devastating symptoms.
The opening of the lab will be a major achievement not just for Fisher-Hoch but for Merieux as well, whose father, Marcel Merieux, was a student of Louis Pasteur and founder of one of the world's oldest pharmaceutical and vaccine companies. Charles Merieux, now 91 years old, spent years trying to convince French and European authorities to build such a lab. Fisher-Hoch says that "the countries in Europe have very strong links with Africa, ... [and they] should have something to contribute scientifically." Although everyone seemed to agree that it was necessary, no one came up with the money. Finally, Merieux decided to build the lab himself with funds from the family foundation he created in the late 1960s when the Merieux group of companies was taken over by French pharmaceutical giant Rhone-Poulenc Rorer.
Fisher-Hoch faced quite a task in making Merieux's dream a reality. Lee Alderman, the former biosafety officer at CDC's BSL4 facility and now the biosafety officer for the Emory University School of Medicine in Atlanta, says that "since there are very few BSL4 laboratories in the world, there is limited experience in designing and building them." Alderman, one of several experts advising Fisher-Hoch on the lab's construction, notes that the Lyons lab presented particular challenges because it is being built over the old Pasteur Institute building--which has now been taken over by the Merieux group--atop six metal and concrete pillars. As a result, while the CDC facility is constructed largely of concrete and resembles a medieval fortress, the walls of the Lyons lab are made from lightweight metal panels filled with polyurethane to avoid crushing the structure below.
Like other BSL4 labs, the air pressure inside the lab will be kept lower than that outside at all times, so that if any leaks suddenly develop air will rush in and prevent microbes from escaping. The air will be recirculated 25 times each hour through special filters designed to capture the smallest virus, and all liquid wastes will be heated to high temperature for several hours before being removed from the lab.
Although the Lyons lab is being built with private foundation funds, Merieux told Science that he expects it will eventually be managed by French public research agencies. Indeed, a number of new research units, many affiliated with the biomedical research agency INSERM, will take up residence in an adjacent building and perform research in the facility. Fisher-Hoch hopes the lab also will eventually become part of the World Health Organization's (WHO's) network of consulting centers, which constitutes a worldwide early-warning system against infectious diseases. David Heymann, director of WHO's division of emerging and other communicable diseases, says the organization would welcome having a top-security lab so close to its Geneva headquarters. "There is a great need in the world for civilian [BSL4] labs where collaborative research can be done." 
